Adalat cc and C-reactive protein increased - a phase IV clinical study of FDA data

Summary:

C-reactive protein increased is reported as a side effect among people who take Adalat cc (nifedipine), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lasix, and have Metastatic renal cell carcinoma.

The phase IV clinical study analyzes which people have C-reactive protein increased when taking Adalat cc. It is created by eHealthMe based on reports of 4,914 people who have side effects when taking Adalat cc from the FDA, and is updated regularly.

What is Adalat cc?

Adalat cc has active ingredients of nifedipine. It is often used in high blood pressure. eHealthMe is studying from 5,019 Adalat cc users. Check the latest studies of Adalat cc.

What is C-reactive protein increased?

C-reactive protein increased is found to be associated with 1,567 drugs and 2,281 conditions by eHealthMe. Check the latest studies of C-reactive protein increased.

On Jul, 05, 2026

4,914 people reported to have side effects when taking Adalat cc.
Among them, 83 people (1.69%) have C-reactive protein increased.

Could Adalat cc cause C-reactive protein increased?

Among these 83 people:

How long have people been on Adalat cc when they have C-reactive protein increased? *

What is the gender of people who have C-reactive protein increased when taking Adalat cc? *

female: 24.39 %
male: 75.61 %

What is the age of people who have C-reactive protein increased when taking Adalat cc? *

What are other drugs people take besides Adalat cc? *

What are other side effects people have besides C-reactive protein increased? *

Fever: 23 people, 27.71%
White Blood Cell Count Increased: 14 people, 16.87%
Blood Creatinine Increased: 14 people, 16.87%
Haemoglobin Decreased: 13 people, 15.66%
Blood Lactate Dehydrogenase Increased: 13 people, 15.66%
Blood Urea Increased: 11 people, 13.25%
Interstitial Lung Disease: 11 people, 13.25%
Haematocrit Decreased: 11 people, 13.25%
Red Blood Cell Count Decreased: 10 people, 12.05%
Oxygen Saturation Decreased: 7 people, 8.43%

What are the existing conditions these people have? *

Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 13 people, 15.66%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 9 people, 10.84%
Diabetes: 6 people, 7.23%
Back Pain: 5 people, 6.02%
Gastritis (inflammation of stomach): 4 people, 4.82%
Herpes Zoster: 4 people, 4.82%
High Blood Cholesterol: 4 people, 4.82%
Colon Cancer: 4 people, 4.82%
Constipation: 4 people, 4.82%
Gastric Ulcer (stomach ulcer): 3 people, 3.61%

* Approximation only. Some reports may have incomplete information.

Do you take Adalat cc and have C-reactive protein increased?

- Check whether C-reactive protein increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adalat cc:

Adalat cc (5,019 reports)

Browse all side effects of Adalat cc:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with C-reactive protein increased:

C-reactive protein increased (1,567 drugs)

Browse all the conditions that are associated with C-reactive protein increased:

C-reactive protein increased (2,281 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nifedipine (the active ingredients of Adalat cc) and Adalat cc (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.